GT Biopharma, Inc. announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation antibody TriKE for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.228 USD | +4.14% | +1.05% | -57.80% |
26/03 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01/02 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.80% | 4.28M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia